RegeneRx Biopharmaceuticals Inc (NASDAQ:RGRX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Wednesday. They currently have a $1.50 target price on the biopharmaceutical company’s stock, down from their previous target price of $2.00.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.com-unik.info/2017/11/03/hc-wainwright-reiterates-buy-rating-for-regenerx-biopharmaceuticals-inc-rgrx.html.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.
What are top analysts saying about RegeneRx Biopharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for RegeneRx Biopharmaceuticals Inc and related companies.